Latest Headlines

  1. Researchers Identify Potential New Route For Antimalarial Drug Design 5/6/2026

    Researchers from the Universities of Bath and Leeds (UK) have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery.

  2. Simulations Plus And NVIDIA Collaborate To Scale GPU-Accelerated, AI-Assisted Modeling Workflows 5/6/2026

    Simulations Plus, Inc. (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a technical collaboration with NVIDIA focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive modeling applications within the drug development lifecycle.

  3. ZYUS Life Sciences Expands U.S. Patent Portfolio With Second Pain Management Patent 5/5/2026

    ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, announced today that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 12,616,704, entitled CANNABICHROMENE FORMULATION FOR PAIN MANAGEMENT on today's date.

  4. Alloy Therapeutics And Institute For Protein Innovation Announce Strategic Collaboration To Advance Next-Generation Antibody Discovery 5/5/2026

    Alloy Therapeutics, a leading biotechnology ecosystem company, today announced a strategic collaboration with the Institute for Protein Innovation (IPI), a nonprofit leader in protein engineering and in vitro discovery.

  5. SGS Acquires Keystone Bioanalytical, Strengthening End-To-End Drug Development Lifecycle Testing Capabilities For North American Pharma And Biotech Industries 5/4/2026

    SGS, the world's leading testing, inspection and certification company, is pleased to announce that it has acquired Keystone Bioanalytical, a specialized provider of bioanalytical testing services based in Philadelphia, Pennsylvania (United States).

  6. Cellenkos Announces FDA Clearance Of Investigational New Drug (IND) Application For Phase 1b/ 2a Trial Of CK0802 In Steroid-Refractory Graft-versus-Host Disease (GVHD) 5/4/2026

    Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application to initiate a Phase 1b/ 2a clinical trial of CK0802 for the treatment of patients with steroid-refractory graft-versus-host disease (GVHD).

  7. HanchorBio And NYCU Launch AI-Enabled Drug Discovery Collaboration To Advance Next-Generation Biologics 4/30/2026

    HanchorBio Inc., a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and autoimmune diseases, today announced a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.

  8. Huahui Health And BeOne Medicines Enter Into A Global Exclusive Option, License And Collaboration Agreement For Innovative Oncology Drug HH160 4/30/2026

    Huahui Health today announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide.

  9. U.S. FDA Grants Priority Review Of New Drug Application For Gilead's Once-Daily HIV Treatment Of Bictegravir Plus Lenacapavir 4/29/2026

    Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, once-daily single-tablet combination regimen for the treatment of HIV in adults who are virologically suppressed.

  10. Immunome Announces Submission Of New Drug Application To U.S. FDA For Varegacestat For The Treatment Of Adults With Desmoid Tumors 4/29/2026

    Immunome, Inc., a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.